Clinical trials: Essential Hypertension.
Essential Hypertension
FimasaRtan-basEd BP Targets After Drug SwitcHing
The recent hypertension clinical practice guidelines published by American College of Cardiology (ACC) and American Heart Association (AHA) reduced the target BP to 130/80 mmHg, indicating the needs for more aggressive efforts in…
- Trial name
- FRESH (NCT03649646)
- Where
- South Korea
- Volunteers
- 4,542 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers
To evaluate the pharmacokinetic drug interaction after oral concurrent administration of fimasartan and amlodipine in healthy male volunteers
- Trial name
- NCT00938197
- Testing
- Fimasartan, Amlodipine
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients
The purpose of this study is to evaluate the antihypertensive efficacy and changes of neurohormonal markers of fimasartan and atenolol with exaggerated blood pressure response during exercise in essential hypertensive patients.
- Trial name
- NCT01736488
- Testing
- Fimasartan, Atenolol
- Where
- 4 sites in South Korea
- Volunteers
- 25 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT07421388
- Testing
- BR1015-A, BR1015-1, BR1015-2
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension
This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension.
- Trial name
- NCT00367094
- Testing
- Benazepril plus hydrochlorothiazide
- Where
- China
- Volunteers
- 296 people
- Sponsor
- Novartis
Bradycardia, Hypertension, Systolic
Preload and Autonomic Responses With Cardiac Neuromodulation Therapy (CNT) (CS-06)
This investigation will evaluate the effect of RV pacing lead position on cardiac function and the modulation of the autonomic nervous system with Cardiac Neuromodulation Therapy (CNT) pacing signals.
- Trial name
- CS-06 (NCT04463121)
- Testing
- Moderato IPG's CNT pacing signals, CD Leycom Pressure/Volume Combination Catheters
- Where
- Czechia
- Volunteers
- 22 people
- Sponsor
- BackBeat Medical Inc
Hypertension,Essential
An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet
This study was to evaluate the therapeutic effect and safety of Amosartan Plus tablet administration in uncontrolled essential hypertension patients.
- Trial name
- NCT05462535
- Testing
- Amosartan Plus Tab.
- Where
- South Korea
- Volunteers
- 4,785 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Mild Hypertension
A Study in People With Mild Hypertension
The primary objective of this study is to test the hypothesis that LY518674, administered for 6 weeks to patients with mild hypertension, reduces Systolic Blood Pressure, compared with placebo.
- Trial name
- NCT00374855
- Testing
- PPAR alpha, Hydrochlorothiazide
- Where
- 10 sites in Sweden
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Essential Arterial Hypertension
Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension
Phase IIIb, randomized, double-blind, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination of losartan / chlorthalidone compared with losartan / hydrochlorothiazide in the treatment of…
- Trial name
- NCT04927299
- Testing
- Losartan/Chlorthalidone in fixed dose, Losartan + hydrochlorothiazide in fixed dose
- Where
- Mexico
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Hypertension
RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment
To support physicians in their active management of hypertensive patients. By targeting specific systolic and diastolic blood pressure (BP) figures physicians will closely monitor the BP values and as such will have an…
- Trial name
- RIAT (NCT00258921)
- Volunteers
- 31,870 people
- Sponsor
- Sanofi
Essential Hypertension
Fimasartan/Amlodipine Combination Phase III
The aim of this study is to ensure the superiority of Fimasartan/Amlodipine combination in hypotensive effect after 8 weeks of treatment over Fimasartan monotherapy in patients with hypertension who have no response to Fimasartan…
- Trial name
- NCT02152306
- Testing
- Fimasartan and Amlodipine, Fimasartan
- Where
- South Korea
- Volunteers
- 143 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension
This study assessed the efficacy of LCZ696 in Japanese patients with essential hypertension
- Trial name
- NCT01599104
- Testing
- LCZ696, Olmesartan
- Where
- 61 sites in Japan
- Volunteers
- 1,161 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Micardis® in Patients With Essential Hypertension
The aim of this observational study was to supplement the data on efficacy, safety, and tolerability of telmisartan under daily conditions in hospitals
- Trial name
- NCT02187705
- Testing
- Telmisartan tablets
- Volunteers
- 1,688 people
- Sponsor
- Boehringer Ingelheim
Hypertension
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
The purpose of this study is to collect the long-term (12 months) safety data on aliskiren 300 mg when taken in combination with HCTZ 25 mg.
- Trial name
- NCT00171405
- Testing
- aliskiren
- Where
- 10 sites in United States, Belgium and 8 more
- Volunteers
- 250 people
- Sponsor
- Novartis
Essential Hypertension
Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension
The purpose of this study is to compare the safety and tolerability of azilsartan medoxomil plus chlorthalidone, once daily (QD), versus olmesartan medoxomil-hydrochlorothiazide in adults with essential hypertension.
- Trial name
- NCT00996281
- Testing
- Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide
- Where
- 26 sites in Austria, Germany and 3 more
- Volunteers
- 837 people
- Sponsor
- Takeda
Essential Hypertension
Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients
Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison with Telmisartan/Amlodipine Combination for Essential Hypertension…
- Trial name
- NCT02738632
- Testing
- Telmisartan/Amlodipine+Hydrochlorothiazide, Telmisartan/Amlodipine
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Hypertension, Hypertension, Systolic
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure…
- Conditions
- Hypertension, Hypertension, Systolic, Hypertension, Essential
- Trial name
- BACKBEAT (NCT06059638)
- Testing
- Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
- Where
- 131 sites in United States, Australia and 13 more
- Volunteers
- 316 people
- Sponsor
- Orchestra BioMed, Inc
Hypertension
MK-0954E Study in Participants With Hypertension (MK-0954E-357)
This study is being done to evaluate the efficacy, safety, and tolerability of losartan potassium 50 mg (L50) + hydrochlorothiazide 12.5 mg (H12.5) + amlodipine besylate 5 mg (A5) (MK-0954E).
- Trial name
- NCT01302691
- Testing
- losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E), Losartan potassium, Amlodipine besylate
- Volunteers
- 327 people
- Sponsor
- Merck Sharp & Dohme LLC
Essential Hypertension
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2…
- Trial name
- Benibest (NCT00890591)
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Volunteers
- 144 people
- Sponsor
- Daiichi Sankyo
Hypertension, Hypercholesterolemia
Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol
The goal of this clinical trial is to test whether one pill that combines ezetimibe, rosuvastatin, and amlodipine can safely lower cholesterol and blood pressure in Korean adults with high blood pressure and high cholesterol.
- Trial name
- NCT07564726
- Testing
- Amlodipine, Ezetimibe/Rosuvastatin
- Where
- 21 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- Celltrion Pharm, Inc.